2026 MS Healthcare Conference: Day 2 Biopharma Takeaways

Research evidence excerpt

Not for redistribution without written consent of Morgan Stanley

M

Idea

September 15, 2026 10:10 PM GMT

Biopharma | North America

Morgan Stanley & Co. LLC

Terence C Flynn, Ph.D.

Equity Analyst

2026 MS Healthcare

Conference: Day 2 Biopharma

Takeaways

Chris Yu, J.D., Ph.D.

Equity Analyst

Connor M Massari

Equity Analyst

Alexander Yevdokimov, Ph.D.

Research Associate

We provide key takeaways from ABBV, AMGN, BHVN, GILD, and

RCUS presentations at our 2026 Global Healthcare Conference,

as well as our management dinner with GILD.

Hailey Horowitz

Research Associate

Damien H Kerner

Research Associate

The discussions covered a range of topics including: (1) new product cycles in-focus

(ABBV's Vyalev, and GILD's Yeztugo and Bixlenvo), (2) pipeline catalysts (ABBV Ph2

Morgan Stanley India Company Private Limited+

immunology combos, AMGN's Dazodalibep Ph3 (2H26) and MariTide Ph3 (2027),

and lateral implications from NVS's recent pelacarsen Ph3 data, BHVN's Opakalim

Saket Agarwal

Research Associate

Ph2/3 (2H26), GILD's Anito-cel (Dec. PDUFA), and RCUS's Ph1/2 Casdatifan), (3)

Policy (PBMs and 340B program) and (4) Capital allocation and M&A/business

development views (ABBV, AMGN, and GILD). See within for more details.

Morgan Stanley does and seeks to do business with

companies covered in Morgan Stanley Research. As a result,

investors should be aware that the firm may have a conflict of

interest that could affect the objectivity of Morgan Stanley

Research. Investors should consider Morgan Stanley

Research as only a single factor in making their investment

decision.